Evidence map›Paper›PMID 29030084›Full record

ArticleExperimental hematology2018

Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain.

Denise K Walters, Bonnie K Arendt, Renee C Tschumper, Xiaosheng Wu, Diane F Jelinek

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental hematology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Denise K WaltersDepartment of Immunology, Mayo Clinic, College of Medicine, Rochester, MN, USA.
Bonnie K ArendtDepartment of Immunology, Mayo Clinic, College of Medicine, Rochester, MN, USA.
Renee C TschumperDepartment of Immunology, Mayo Clinic, College of Medicine, Rochester, MN, USA.
Xiaosheng WuDepartment of Immunology, Mayo Clinic, College of Medicine, Rochester, MN, USA.
Diane F JelinekDepartment of Immunology, Mayo Clinic, College of Medicine, Rochester, MN, USA. Electronic address: jelinek.diane@mayo.edu.
Mayo Clinic · US

Funding

Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Rafael Fonseca · 2015 to 2026
$25.5M
Tumor Cell-Intrinsic/Extrinsic Mechanisms Underlying Myeloma Disease ProgressionR01CA196831 · NCI · MAYO CLINIC ROCHESTER · PI JELINEK, DIANE F · 2015 to 2019
$1.8M
NCI NIH HHS P50 CA186781NCI NIH HHS R01 CA196831
6 · The paper itself

Abstract

The genetic abnormalities underlying multiple myeloma (MM) are notoriously complex and intraclonal heterogeneity is a common disease feature. In the current study, we describe the establishment of a monoclonal immunoglobulin A (IgA) kappa (κ) MM cell line designated MC-B11/14. Cytogenetic and fluorescence in situ hybridization analyses of the original and relapse patient samples revealed that the MM clone was nonhyperdiploid and possessed an 11;14 chromosomal translocation. The MC-B11/14 cell line, established from the relapse sample, is tetraploid and houses the t(11;14) abnormality. Given our long-standing interest in Ig function and secretion, we next used CRISPR technology to knock out IgA heavy-chain expression in the MC-B11/14 cells to assess the biological consequences of converting this cell line to one only expressing κ light chains. As expected, secretion of intact IgA was undetectable from MC-B11/14

Indexed as

Cell Line, TumorCRISPR-Cas SystemsGene Knockout TechniquesGenes, ImmunoglobulinAmino Acid SequenceAntineoplastic Combined Chemotherapy ProtocolsBase SequenceBone Marrow TransplantationBortezomibChromosomes, Human, Pair 11Chromosomes, Human, Pair 14Combined Modality TherapyFatal OutcomeGene Expression Regulation, NeoplasticHumansImmunoglobulin ABortezomibImmunoglobulin AImmunoglobulin Heavy ChainsImmunoglobulin kappa-ChainsMyeloma ProteinspomalidomideThalidomide

Identifiers

PMID29030084
PMCPMC5716910
OpenAlexW2762302377

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.